Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine | ||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 25 Jun 2019 | Back to overview list |
|||||||||||||||||||||||||||
Nina Church joins as Executive Director of Global Clinical Development and Nancy Herje as Senior Director of Clinical Operations LONDON, June 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase 3 program for Verona Pharma’s first-in-class product candidate, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). Nina Church joins as Executive Director of Global Clinical Development and Nancy Herje as Senior Director of Clinical Operations. They strengthen Verona Pharma’s clinical team led by Kathleen Rickard, MD, Chief Medical Officer, and will be based in the Company’s US office. “We are delighted to welcome Nancy and Nina to Verona Pharma,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “They bring substantial expertise in respiratory drug development and a strong track record of planning and managing global clinical trial programs. We believe ensifentrine, with its unique mode of action and clinical profile, has a very attractive commercial potential. We plan to complete our Phase 2 program with nebulized ensifentrine with data expected around year end and to enter pivotal Phase 3 trials in 2020.” Ms. Church brings 30 years of experience of late-stage clinical drug development in respiratory therapeutics, with 25 years at GlaxoSmithKline where she held a series of management positions, including Director, Global Operations COPD. At GlaxoSmithKline, Ms. Church was involved in the development of many respiratory therapeutics including Advair®, Anoro®, Flovent®, Serevent® and Ventolin®. She joins from Parion Sciences where she was Executive Director, Clinical Operations. Ms. Herje has more than 25 years of experience in designing, planning and executing clinical programs for pharmaceutical and medical device companies including trials for the COPD therapeutic Flovent®. Prior to joining Verona Pharma, Nancy was a Senior Clinical Scientist at ExecuPharm and previously held roles at Chimerix, Aerocrine, Inspire and GlaxoSmithKline. About COPD About Verona Pharma plc Ensifentrine has shown significant and clinically meaningful improvements in both lung function and COPD symptoms, including breathlessness, in prior Phase 2 clinical studies in patients with moderate-to-severe COPD. In addition, ensifentrine has further improved lung function and reduced lung volumes in patients taking standard short- and long-acting bronchodilator therapy, including maximum bronchodilator treatment with dual/triple therapy. Ensifentrine has been well tolerated in clinical trials involving more than 800 people to date. Forward-Looking Statements These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our research and development efforts and the completion of our Phase 2b trial; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 19, 2019, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. For further information, please contact:
|
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |